On Jan. 21, the U.S. Food and Drug Administration took two actions to expand the use of Gilead’s antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease.
Previously, the use of Veklury was limited to patients requiring hospitalization.
Your patients survive. That costs Methodist pall the COVID kill money. Remdesivir, ventilator and the bonus for killing the patient.
— Thomas A. B. Johnson (@agent21) January 24, 2022
The FDA expanded the approved indication for Veklury to include its use in adults and pediatric patients (12 years of age and older who weigh at least 40 kilograms) who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19.
#FDAapproves treatment for non-hospitalized adults and pediatric patients 12 yrs and older weighing at least 40 kg with mild-to-moderate #COVID19 who are at high risk for progression to severe disease, including hospitalization or death: https://t.co/pu1CbvfX39 pic.twitter.com/0vu9XC21Zx
— FDA Drug Information (@FDA_Drug_Info) January 22, 2022
The agency also revised the EUA for Veklury to additionally authorize it for treatment of pediatric patients weighing 3.5 to 40 kilograms, or patients less than 12 years of age weighing at least 3.5 kilograms, who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19.
How many of you would love to see an influencer like @joerogan have an open discussion about remdesivir?
— RemdesivirLawsuitGroup (@XRadarP) January 18, 2022
Millions of people need to learn about this failed drug protocol.
These high-risk non-hospitalized patients may receive Veklury via intravenous infusion for a total of three days for the treatment of mild-to-moderate COVID-19 disease, and pediatric patients fowill receive doses adjusted for their body weight to achieve comparable exposures to adults and pediatric patients receiving the approved dose.